Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances

Bruton’s tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new drug approval. The first-in-class drug ibrutinib creates possibilities for an era of chemotherapy-free management of B...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Tingyu, Wang, Jinsong, Shi, Yuankai, Qian, Haili, Liu, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862069/
https://www.ncbi.nlm.nih.gov/pubmed/33122850
http://dx.doi.org/10.1038/s41375-020-01072-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862069/
https://www.ncbi.nlm.nih.gov/pubmed/33122850
http://dx.doi.org/10.1038/s41375-020-01072-6

Ejemplares similares